Sus Clinicals
Sus Clinicals commercializes the FDA-cleared Oncopig Cancer Model, a genetically-engineered porcine platform for preclinical cancer drug, device, and diagnostic testing. The Cincinnati-based CRO serves pharmaceutical, medical device, academic, and diagnostics clients via preferred CRO partnerships and direct institution supply.
- Company typePrivate
- Founded2020
- HeadquartersCincinnati, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Sus Clinicals does
Sus Clinicals is a Cincinnati-headquartered preclinical contract research organization founded in 2020 that commercializes the Oncopig Cancer Model (OCM), an FDA-cleared genetically-engineered porcine platform for cancer drug, device, and diagnostic testing. The model leverages the physiological similarity between pigs and humans (Sus scrofa) to enable site- and time-specific tumor induction, with CRISPR-introducible driver mutations (KRAS, TP53, PTEN, KEAP1) supporting both broad screening and personalized-therapy preclinical programs. The platform is positioned to bridge the predictive gap between mouse models and human clinical trials by enabling testing of medical devices, radiation, and intervention regimens not feasible in rodents, and by allowing introduction of comorbidities such as cirrhosis alongside liver cancer.
The company monetizes the platform through three delivery models: a preferred CRO partnership channel leveraging top-tier preclinical research organizations (CBSET, IBEX, NAMSA, MED Institute, Veranex); direct Oncopig supply to academic and industry clients with established animal research facilities, bundled with training and technical support; and European research services via a partnership with Versa Biomedical in Barcelona. End customers span pharmaceutical and biotechnology companies, medical device developers, academic and research institutions, and diagnostics companies, with engagements customized per research program and pricing not publicly disclosed.
Sus Clinicals is a University of Illinois spin-out that holds an exclusive global license to the Oncopig Cancer Model IP, originally developed by co-founder and CSO Dr. Lawrence Schook. It received FDA Enforcement Discretion in April 2022, a $2M NIH SBIR grant in October 2023, and had $3.5M of a $5M exempt securities offering sold by January 2024. Leadership combines P&G-trained co-founder and Executive Chair Jeffrey Weedman with a recently installed CEO, Dr. Jessicca Rege (appointed August 2024), whose background includes senior oncology development roles at Mural Oncology, Alkermes, OncXerna, Daiichi-Sankyo, Eli Lilly, and Eisai.
Sus Clinicals firmographics
Firmographics- Name
- Sus Clinicals
- Legal name
- Sus Clinicals, Inc.
- Website
- https://susclinicals.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sus Clinicals commercializes the FDA-cleared Oncopig Cancer Model, a genetically-engineered porcine platform for preclinical cancer drug, device, and diagnostic testing. The Cincinnati-based CRO serves pharmaceutical, medical device, academic, and diagnostics clients via preferred CRO partnerships and direct institution supply.
- Ownership category
- akta.pro rank
Sus Clinicals industry classification
Industry- Product category
- Preclinical Cancer Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where Sus Clinicals is headquartered
LocationHeadquarters
- HQ city
- Cincinnati
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Sus Clinicals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Preclinical Testing Services: Sus Clinicals provides preclinical testing services to pharmaceutical, medical device, diagnostics, and immunotherapy companies through its Oncopig platform. Services include CRO partnership model, direct institution supply, and European research services through Versa Biomedical.
- Oncopig Supply and Training: Direct supply of Oncopigs to academic and industry clients with established animal research facilities, including comprehensive training, methodology guidance, and ongoing technical support.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Sus Clinicals product offering
Product offeringCore offering
Sus Clinicals provides preclinical cancer research services using the Oncopig Cancer Model (OCM), a proprietary FDA-cleared genetically-engineered large animal (porcine) platform that enables site- and time-specific tumor induction for predictive testing of oncology drugs, medical devices, diagnostics, and immunotherapies. The company delivers these services through three engagement pathways: a CRO Partnership Model with top-tier clinical research organizations, Direct Institution Supply for clients with their own facilities, and European Research Services via a partnership with Versa Biomedical in Barcelona.
Product overview
Sus Clinicals operates as a preclinical contract research organization offering the Oncopig Cancer Model (OCM), a proprietary FDA-cleared genetically-engineered porcine platform for cancer research. The company's core offering consists of the Oncopig platform combined with three flexible service delivery models: the CRO Partnership Model (leveraging preferred partner CROs like CBSET, IBEX, NAMSA, MED Institute, and Veranex), Direct Institution Supply (for clients with their own facilities), and European Research Services (via Versa Biomedical in Barcelona). An emerging product variant, the Miniature Oncopig, is in development for pharmaceutical testing applications.
Differentiator
Problem solved
Functional benefit
Brands
- Oncopig Cancer Model (OCM): FDA-cleared genetically-engineered large animal platform for preclinical cancer research enabling tumor induction on demand for testing drugs, devices, and diagnostics.
- Miniature Oncopig
Products and services
- Oncopig Cancer Model (OCM) Proprietary FDA-cleared genetically-engineered large animal (porcine) platform that enables site- and time-specific tumor induction for preclinical testing of oncology drugs, devices, diagnostics, and immunotherapies, providing predictive data that bridges mouse models and human clinical trials. Offered to pharmaceutical, biotechnology, medical device, diagnostics, and academic research clients.
- CRO Partnership Model Preferred service delivery pathway that leverages partnerships with top-tier clinical research organizations (CBSET, IBEX Preclinical Research, NAMSA, MED Institute, Veranex) equipped with AAALAC-accredited facilities, regulatory expertise, and data management capabilities to execute Oncopig studies for pharmaceutical, biotech, and medical device clients.
- Direct Institution Supply
- European Research Services
- Miniature Oncopig
Companies that use Sus Clinicals
Customer profileSegments4 records
Ideal customer profiles3 records
Sus Clinicals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Sus Clinicals partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, preferred and minor.
- IBEX Preclinical ResearchcoreIBEX Preclinical Research, a leading med tech CRO for preclinical surgical studies across a variety of laboratory animal species, announced collaborative relationship with Sus Clinicals to better serve the medical device industry and accelerate clients' oncologic innovations. The partnership extends research services by providing access to the inducible transgenic large animal platform.
- MED InstitutecoreMED Institute, a leader in pre-clinical and clinical medical product development services, announced strategic collaboration with Sus Clinicals to enhance preclinical testing for medical products. The partnership combines expertise in engineering, regulatory strategy, and large animal disease models to accelerate development and improve outcomes for medical product manufacturers worldwide.
- Versa BiomedicalcorePartnership with Versa Biomedical in Barcelona enables delivery of localized Oncopig research services to clients in Europe. The partnership combines Sus Clinicals' platform expertise with regional infrastructure and expertise, offering local European CRO expertise, streamlined logistics and compliance, and integrated scientific support.
- CBSETpreferredOne of Sus Clinicals' preferred CRO partners for Oncopig studies, providing preclinical research services including the Y-90 pancreatic cancer study in collaboration with BetaGlue.
- NAMSApreferredPreferred CRO partner equipped with the expertise, facilities, and regulatory compliance needed for rigorous Oncopig studies.
- VeranexpreferredPreferred CRO partner providing preclinical research services with expertise in medical device testing using the Oncopig platform.
- BetaGlueminorBetaGlue sponsored Y-90 research collaboration with Sus Clinicals and CBSET for preclinical safety and efficacy evaluation of Yttrium-90 Resin Microsphere Glue Formulation in the Oncopig Pancreatic Cancer Model.
- University of IllinoiscoreSus Clinicals is the exclusive global licensee of intellectual property from the University of Illinois related to the Oncopig Cancer Model. The OCM was pioneered by Dr. Lawrence Schook and his team at UI. The partnership includes continued collaboration for development of new Oncopig models.
- University of Wisconsin-MadisonminorCollaboration with University of Wisconsin-Madison for development of the Miniature Oncopig cancer model, an innovative large animal platform for preclinical pharmaceutical evaluation.
- University of Illinois-ChicagominorCollaboration with University of Illinois-Chicago for development of the Miniature Oncopig cancer model for preclinical pharmaceutical evaluation.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Sus Clinicals competitors and assessment
Company assessmentBroad incumbents
- Charles River Laboratories: Global preclinical CRO offering safety assessment, oncology, and large-animal services across thousands of clients. Directly comparable as a broad incumbent in the preclinical CRO space where Sus Clinicals competes, though Charles River offers a much wider service portfolio.
- Labcorp Drug Development (formerly Covance): One of the largest preclinical and clinical CROs globally, providing oncology and medical-device testing services. Overlaps with Sus Clinicals on preclinical oncology and medical-device studies, though at vastly greater scale and broader service scope.
- Wuxi AppTec: Large CRO/CDMO providing preclinical safety, oncology, and biologics services globally with significant large-animal capabilities. Overlaps with Sus Clinicals on preclinical oncology and medical-device testing, though Wuxi is dramatically larger and more diversified.
Direct peers
- Inotiv: Pure-play preclinical CRO with research models and contract research services, including large-animal and device safety studies. Comparable as a mid-sized preclinical CRO competing in similar oncology and device preclinical testing workflows as Sus Clinicals.
- Champions Oncology: Oncology-focused preclinical services company using patient-derived xenograft (PDX) and ex vivo platforms to support pharma translational research. Direct peer in providing predictive preclinical oncology data, though it uses mouse-based rather than large-animal models.
- Crown Bioscience: Global oncology-focused preclinical CRO offering PDX, organoid, and in vivo pharmacology services for pharma and biotech sponsors. Closely comparable as a specialty oncology preclinical CRO addressing similar translational research needs as Sus Clinicals.
- CBSET: Preclinical CRO specializing in medical device and drug safety studies in large-animal models. Acts as a Sus Clinicals preferred partner but is also a direct comparable peer offering similar large-animal preclinical services, including the Y-90 pancreatic cancer study with BetaGlue.
- IBEX Preclinical Research: Med-tech CRO focused on preclinical surgical studies across multiple laboratory animal species including large animals. Announced a strategic collaboration with Sus Clinicals in April 2026, but operates in the same large-animal medical-device preclinical testing market.
- NAMSA: Premier medical-device preclinical and clinical CRO with extensive large-animal testing capabilities. Preferred Sus Clinicals partner but also a directly comparable peer in the medical-device preclinical CRO market.
- MED Institute: Pre-clinical and clinical medical product development services provider with expertise in engineering, regulatory strategy, and large-animal disease models. Announced strategic collaboration with Sus Clinicals in December 2025 but remains a directly comparable peer in medical-device preclinical testing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Sus Clinicals social profiles
Digital presenceSus Clinicals compliance and trust
Trust signalCompliance1 record
Sus Clinicals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sus Clinicals leadership team
Management profileNumber of profiles
Profiles7 records
Sus Clinicals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sus Clinicals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sus Clinicals
What does Sus Clinicals do?
Sus Clinicals provides preclinical cancer research services using the Oncopig Cancer Model (OCM), a proprietary FDA-cleared genetically-engineered large animal (porcine) platform that enables site- and time-specific tumor induction for predictive testing of oncology drugs, medical devices, diagnostics, and immunotherapies. The company delivers these services through three engagement pathways: a CRO Partnership Model with top-tier clinical research organizations, Direct Institution Supply for clients with their own facilities, and European Research Services via a partnership with Versa Biomedical in Barcelona.
Is Sus Clinicals a public or private company?
Sus Clinicals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sus Clinicals founded?
Sus Clinicals was founded in 2020. It employs 1 to 10 people.
Where is Sus Clinicals based?
Sus Clinicals is headquartered in Cincinnati, United States, in the North America region.
How does Sus Clinicals make money?
Two revenue lines are on record. Preclinical Testing Services are the primary driver. The others are oncopig Supply and Training.
Who are Sus Clinicals's main competitors?
Broad incumbents on record are Charles River Laboratories, Labcorp Drug Development (formerly Covance) and Wuxi AppTec. Direct peers are Inotiv, Champions Oncology, Crown Bioscience, CBSET, IBEX Preclinical Research, NAMSA and MED Institute.
Does Sus Clinicals have an API?
No public API is recorded for Sus Clinicals.
What industry is Sus Clinicals in?
Sus Clinicals's product category is Preclinical Cancer Research Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.